



Research Paper

Sodium sulfide selectively induces oxidative stress, DNA damage, and mitochondrial dysfunction and radiosensitizes glioblastoma (GBM) cells.



Adam Y. Xiao^a, Matthew R. Maynard^b, Cortt G. Piatt^c, Zachary D. Nagel^c, J. Steven Alexander^a, Christopher G. Kevil^d, Michael V. Berridge^e, Christopher B. Pattillo^a, Lane R. Rosen^b, Sumitra Miriyala^f, Lynn Harrison^{a,*}

^a Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA

^b Radiation Oncology, Willis-Knighton Cancer Center, Shreveport, LA, 71103, USA

^c Harvard University, School of Public Health, Boston, MA, 02115, USA

^d Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA

^e Malaghan Institute of Medical Research, Wellington, 6242, New Zealand

^f Department of Cell Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA

ARTICLE INFO

Keywords:

Hydrogen sulfide
Glioblastoma
Ionizing radiation
DNA damage
DNA repair
Mitochondria
Reactive oxygen species

ABSTRACT

Glioblastoma (GBM) has a poor prognosis despite intensive treatment with surgery and chemoradiotherapy. Previous studies using dose-escalated radiotherapy have demonstrated improved survival; however, increased rates of radionecrosis have limited its use. Development of radiosensitizers could improve patient outcome. In the present study, we report the use of sodium sulfide (Na₂S), a hydrogen sulfide (H₂S) donor, to selectively kill GBM cells (T98G and U87) while sparing normal human cerebral microvascular endothelial cells (hCMEC/D3). Na₂S also decreased mitochondrial respiration, increased oxidative stress and induced γH2AX foci and oxidative base damage in GBM cells. Since Na₂S did not significantly alter T98G capacity to perform non-homologous end-joining or base excision repair, it is possible that GBM cell killing could be attributed to increased damage induction due to enhanced reactive oxygen species production. Interestingly, Na₂S enhanced mitochondrial respiration, produced a more reducing environment and did not induce high levels of DNA damage in hCMEC/D3. Taken together, this data suggests involvement of mitochondrial respiration in Na₂S toxicity in GBM cells. The fact that survival of LN-18 GBM cells lacking mitochondrial DNA (ρ⁰) was not altered by Na₂S whereas the survival of LN-18 ρ⁺ cells was compromised supports this conclusion. When cells were treated with Na₂S and photon or proton radiation, GBM cell killing was enhanced, which opens the possibility of H₂S being a radiosensitizer. Therefore, this study provides the first evidence that H₂S donors could be used in GBM therapy to potentiate radiation-induced killing.

1. Introduction

Glioblastoma multiforme (GBM) is the most common malignant central nervous system (CNS) cancer in adults accounting for 55% of all gliomas [1]. It is a rapidly progressing, life-threatening disease with a median survival of 14.6 months following maximal safe surgical resection and photon radiotherapy (60 Gy in 30 fractions) with concomitant and adjuvant temozolomide (TMZ), an alkylating agent [2]. The poor survival despite intensive treatment highlights a need for novel therapy. Several clinical trials in GBM have found that dose escalation with either intensity modulated radiation therapy (IMRT) or

protons increases median survival up to 21 months; however, there is an increased risk of radiation necrosis that makes the survival benefit unclear [3–6]. The brain vasculature is a critical mediator of radiation necrosis. Endothelial cell apoptosis after ionizing radiation (IR) can cause blood-brain barrier disruption and leukocyte extravasation leading to tissue necrosis [7]. Radiosensitization agents may overcome this problem by allowing for the use of lower doses to achieve comparable cytotoxic effects; however, no radiosensitizers are currently approved for the treatment of GBM [8].

Hydrogen sulfide (H₂S) is the second leading cause of inhalational deaths and exposure to 500 ppm can be fatal [9]. However, it is now

* Corresponding author. Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA, 71130, USA.

E-mail address: lclary@lsuhsc.edu (L. Harrison).

<https://doi.org/10.1016/j.redox.2019.101220>

Received 9 April 2019; Received in revised form 4 May 2019; Accepted 13 May 2019

Available online 16 May 2019

2213-2317/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

understood that H₂S is an endogenous gasotransmitter [10]. It is synthesized in most cells of the body by three different enzymes: cystathionine γ -lyase (CSE), cystathionine β -synthase (CBS), and 3-mercaptopyruvate sulfurtransferase (3-MST). In aqueous solution, H₂S dissociates at 37 °C, pH 7.4 and exists as H₂S, HS⁻, or S²⁻. H₂S, HS⁻ and S²⁻ collectively are known as hydrogen sulfide in biological systems. H₂S *in vivo* primarily exists as HS⁻ and can alter enzyme activity and cell signaling predominantly by the addition of sulfhydryl groups to proteins [11]. H₂S is therefore involved in various physiologic processes and at low levels, protects the cardiovascular system against damage [12]. In the brain, H₂S can act as an antioxidant. It increases cytoplasmic and mitochondrial glutathione in neurons and protects against glutamate toxicity [13,14]. It also attenuates methionine-induced oxidative stress in brain endothelial cells [15].

The role of H₂S in cancer biology is less clear and has been a subject of continued debate with studies citing either pro-cancer or anti-cancer effects depending on the cancer type as well as H₂S concentration [16]. Upregulation of CBS in colon cancer promotes proliferation and angiogenesis [17]. In contrast, 3-MST is downregulated in astrocytoma and knockdown of CBS promotes GBM tumorigenesis suggesting a tumor-suppressing role of H₂S in the brain [18,19]. Use of H₂S donors has also demonstrated anti-cancer effects. The slow-releasing GYY4137 selectively acidifies breast cancer and hepatocellular carcinoma cells but not breast epithelial cells or lung fibroblasts to promote cell death [20]. Several studies have also suggested H₂S acts as a nuclear DNA damaging agent in lung fibroblasts and intestinal epithelial cells; however, this effect has not been studied in cancer [21,22].

To date, no studies have examined the effect of exogenous H₂S on GBM. In the present study, we show that sodium sulfide (Na₂S), a fast-releasing H₂S donor, selectively kills GBM cells while sparing normal brain endothelial cells by increasing DNA damage through a ROS-dependent mechanism. Furthermore, this is the first work demonstrating that Na₂S, and hence H₂S, can selectively radiosensitize GBM cells in culture to photon or proton radiation. This therefore supports future studies into the development of H₂S-releasing compounds as clinical radiosensitizers to selectively kill GBM tumor cells.

2. Materials and methods

2.1. Cell culture

Human T98G and U87 cells (ATCC) were cultured in EMEM medium supplemented with 10% fetal bovine serum (FBS). Human cerebral microvascular endothelial cells (hCMEC/D3) were acquired from Dr. Steven Alexander (LSU-Health Shreveport) and cultured in EndoGRO-MV (MilliporeSigma) between passages 32–37 [23]. LN18 and U87 human glioblastoma cell lines from ATCC were used to derive rho-zero (ρ^0) sublines by An Tan (Malaghan Institute of Medical Research, New Zealand). The ρ^+ and ρ^0 LN18 and U87 cell lines were obtained from Michael Berridge (Malaghan Institute of Medical Research, New Zealand) and cultured in DMEM containing 1 mM pyruvate supplemented with 10% FBS and 50 μ g/mL uridine. All cells were grown at 5% CO₂ and routinely tested for mycoplasma.

2.2. PCR to detect mitochondrial DNA

Total DNA was isolated from cells using the QiaAmp DNA mini kit (Qiagen). PCR primers were obtained from Eurofins to amplify regions of DNA corresponding to β actin [Forward: d(ATCATGTTTGAGACCTTCAACA), Reverse: d(CATCTCTTGTCTCGAAGTCCA)] in the nuclear genome or cytochrome b [Forward: d(CTAGCAACACTCCACCTCCTAT), Reverse: d(GTAAGCCGAGGGCGTCTTGCTTG)] in the mitochondrial genome. PCR reactions were performed according to manufacturer's instructions with 1–2 μ g total DNA, Taq DNA polymerase (Promega) and primers to amplify DNA corresponding to β actin (318 bp) or cytochrome b (123 bp) using annealing temperatures of 53 °C or 57 °C,

respectively. PCR products were visualized following gel electrophoresis.

2.3. Hydrogen sulfide treatment

Sodium sulfide (Alfa Aesar), a fast-releasing H₂S donor, was freshly prepared in degassed, deionized water before each treatment. Na₂S from Alfa Aesar has high purity with minimal polysulfide contamination [24]. Cells were treated with either 476 μ M Na₂S or degassed water for 4 h at 37 °C (Fig. 1A). Cells were media changed and new Na₂S added after 2 h due to its short half-life of 5–30 min *in vitro*. [25] Irradiation experiments were performed during the second 2 h incubation.

2.4. Hydrogen sulfide measurements

Free sulfide concentration was measured using HPLC [26]. Cells were treated with either degassed water or 476 μ M Na₂S for a total of 4 h (Fig. 1A) and collected in degassed stabilization buffer (SB; 100 mM Tris-HCl, 0.1 mM DTPA, 0.1% Triton X-100; pH 9.5). The protein concentration was measured using DC™ Protein Assay (Bio-Rad). Subsequent steps were performed in hypoxic conditions. The sample was incubated with 10 mM monobromobimane (MBB) for 30 min. The reaction was stopped with 200 mM 5-sulfosalicylic acid and the sample analyzed by RP-HPLC. Data is expressed as nmol of free sulfide/mg of protein.

2.5. Photon and proton irradiation

Cell cultures were individually irradiated with either proton or photon modalities to physical doses of 2 Gy, 4 Gy, 6 Gy or 10 Gy. For each modality and container geometry, a computed tomography (CT) radiotherapy treatment simulation was performed using a “blank” container. In each case, the simulation was analogous to that of an actual human patient, i.e. the CT imaging parameters were appropriate for dose calculation and the container was aligned using optical lasers to a setup position that was easily reproduced on the radiotherapy machines. For each simulation and subsequent radiation delivery, containers were sandwiched between slabs of radiotherapy-quality water-equivalent plastic to provide appropriate levels of radiation buildup and backscatter. These conditions were necessary for accurate dose calculation and to generate dose distributions that were robust to minor setup errors during radiation delivery. The CT simulation images of the containers were then imported into the RayStation™ treatment planning system (RaySearch Laboratories, Inc.; Stockholm, Sweden) and contoured as necessary (outer boundary, targets, etc.). Treatment plans were then generated for each modality and dose level. In all cases, a single, static beam (oriented above and perpendicular to the cell container) was utilized to deliver the desired dose. Targets were contoured in such a manner that minor setup errors would not affect the dose delivery. Photon irradiations were performed using a 6 MV beam energy on an Elekta VersaHD™ (Elekta, Inc.; Stockholm, Sweden) conventional radiotherapy linear accelerator. Proton irradiations were performed using an energy range of 72 MeV–131 MeV on an Ion Beam Applications (IBA) ProteusONE™ (IBA SA, Louvain-La-Neuve, Belgium) proton therapy gantry. The range of proton energies was necessary due to the pencil beam scanning delivery technique of the machine, which deposits dose at different depths by modulating proton energy.

2.6. Clonogenic assay and DEF calculation

Cells were seeded in cell culture flasks for 4 h before treatment with degassed water or Na₂S. For experiments where cells were also treated with ionizing radiation (IR), cells were exposed to 0–10 Gy during the second Na₂S treatment (Fig. 1A). Cells were then incubated for a defined period of time to allow formation of colonies with > 50 cells

(T98G: 10 days, U87: 11 days, hCMEC/D3: 12 days, LN18 WT: 6 days, LN18 ρ^0 : 21 days). Plating efficiency (PE) was calculated as $PE = \frac{\# \text{ colonies}}{\# \text{ cells plated}}$. The surviving fraction (SF) was defined as $SF = \frac{PE_{\text{treatment}}}{PE_{\text{zero dose}}}$. Survival curves following ionizing radiation were fit to the linear quadratic equation $SF = e^{-\alpha D + \beta D^2}$ where D is the dose. SF for IR with Na₂S was normalized to Na₂S treatment alone to adjust for cytotoxicity from Na₂S. The dose enhancement fraction at 10% survival (DEF₁₀) for Na₂S was defined as $DEF_{10} = \frac{D_{10,IR+Na_2S}}{D_{10,IR}}$. The relative biological effectiveness at 10% survival (RBE₁₀) for protons was defined as $RBE_{10} = \frac{D_{10,photon}}{D_{10,proton}}$, where D₁₀ is the treatment dose that produces 10% surviving fraction.

2.7. γ H2AX staining

γ H2AX foci were stained using immunohistochemistry. Briefly, cells were cultured on glass coverslips and grown to confluency. Following treatment with Na₂S \pm IR (Fig. 1A), cells were either immediately fixed in 4% paraformaldehyde or were incubated 2–24 h prior to fixing. Cells were then lysed, and blocked with 5% normal goat serum. Cells were incubated overnight at 4 °C in anti- γ H2AX antibody (MilliporeSigma, 1:2000), stained with anti-mouse IgG Alexa Fluor 488 secondary antibody (Invitrogen, 1:500) for 1 h, and DAPI (Biotium, 1 μ g/mL). Images were taken using a Nikon Eclipse Ti or Olympus BX43 microscope. The number of foci in 50 cells was counted in each of 3 independent experiments using JCountPro and the data pooled to determine the average number of foci per cell [27].

2.8. Alkaline comet assay

The FPG-modified alkaline comet assay was performed as previously described, with modification [28]. Following treatment with Na₂S \pm IR (Fig. 1A), samples of cells were divided in two and embedded in 6% low-melting point agarose, solidified on agarose coated slides, and incubated in lysis buffer (100 mM EDTA, 2.5 M NaCl, 10 mM Tris-HCl, 1% Triton-X; pH 10) overnight at 4 °C. Slides were equilibrated in enzyme reaction buffer (40 mM HEPES, 0.1 M KCl, 0.6 mM EDTA, 0.2 mg/mL BSA; pH 8). To detect oxidative base damage, one slide of each sample remained in only enzyme reaction buffer, while the second was treated with 8 U/mL of formamidopyrimidine [fapy]-DNA glycosylase (FPG, New England Biolabs). Both slides were incubated for 30 min at 37 °C. Slides were equilibrated and subjected to electrophoresis in alkaline buffer (0.3 M NaOH, 1 mM EDTA) for 20 min at 30 V and 300 mA. DNA was recondensed in neutralization buffer (0.4 M Tris-HCl, pH 7.5) for 20 min, dried overnight, and stained with propidium iodide (1 μ g/mL). Comets were imaged using a Nikon Eclipse Ti and 15X objective. The tail moment was calculated from the tail length and staining intensity of the head and tail using OpenComet (ImageJ) [29]. Approximately 50 cells were analyzed for each of three independent experiments and the average tail moment calculated.

2.9. Quantification of glutathione

Cellular glutathione concentration was measured using high performance liquid chromatography (HPLC) as previously described, with modification [30]. Cells were treated with either degassed water or 476 μ M Na₂S (Fig. 1A) and collected immediately after treatment in 5% TCA. Samples were subjected to centrifugation and the cell pellet was dissolved in 1 M NaOH prior to the total amount of protein being measured using DC™ Protein Assay (Bio-Rad). The supernatant was derivatized with 80 mM iodoacetic acid (pH adjusted to 7–8) and 6% Sanger's dinitrofluorobenzene (pH adjusted to 7). Samples were filtered and applied to a 250 \times 4.6-mm Alltech Lichrosorb NH₂ 10 μ m anion-exchange column to separate reduced (GSH) and oxidized (GSSG) glutathione. The GSH and GSSG per mg protein was calculated.

2.10. ROS assay

CM-H₂DCFDA (Molecular Probes) was used to measure general ROS with or without treatment with 2.5 mM TEMPOL (Enzo Life Sciences). Equal number of cells were seeded into 96 well plates one day prior to treatment. Cells were pre-treated with TEMPOL for 1 h and then 476 μ M Na₂S or degassed water was also added to the cells. After 2 h, the media was replaced and cells were treated again with only 476 μ M Na₂S or degassed water for 2 h. Cells were then incubated with 2 μ M CM-H₂DCFDA for 20 min at 37 °C and washed with PBS. Fluorescent intensity was measured at 485 nm excitation and 520 nm emission and normalized to the degassed water control to calculate relative fluorescent intensity.

2.11. Mitochondrial oxygen consumption

Determination of oxygen consumption rate (OCR) was performed as previously described, with modification [31]. 80,000 cells were seeded onto Seahorse Bioscience XF24 microplates and treated the following morning with either degassed water or 476 μ M Na₂S for a total of 4 h (Fig. 1A). OCR was measured using a Seahorse Bioscience XF24 Extracellular Flux Analyzer. Cells were cultured in DMEM containing 4 mM glutamine (Gibco) and supplemented with 50 mM glucose and 2 mM sodium pyruvate for basal measurements then treated with oligomycin (1 μ M), FCCP (1 μ M), and rotenone/antimycin A (0.5 μ M) to measure OCR. The spare capacity was calculated as the FCCP OCR minus the basal OCR. After OCR measurements, attached cells were dissolved in 0.1 N NaOH for protein analysis with Pierce BCA Protein Assay (ThermoScientific). The OCR was calculated and is expressed as pmol of oxygen consumed per minute per mg protein.

2.12. Mitochondrial complex I and III activity

T98G and hCMEC/D3 cells were treated with either degassed water or 476 μ M Na₂S for a total of 4 h (Fig. 1A). Cell lysates were prepared in 20 mM hypotonic potassium phosphate buffer (pH 7.5) by freezing in liquid nitrogen and thawing at 37 °C three times. The protein concentration was measured using DC™ Protein Assay (Bio-Rad). Complex I and III activity was measured in the cell lysates according to Spinazzi, M et al. [32] Complex I activity was measured as the rotenone-sensitive oxidation of NADH at 340 nm in 50 μ g of protein. Complex III activity was measured as the antimycin A-sensitive oxidation of cytochrome c at 550 nm in 20 μ g of protein. Activities are expressed as nmol conversion of NADH to NAD⁺/min/mg protein for complex I and nmol reduction of oxidized cytochrome c/min/mg for complex III.

2.13. DNA repair assays

Non-homologous end-joining (NHEJ) and base excision repair (BER) capacity were assessed using plasmid reporter assays. For NHEJ, the NHEJ-I vector [33] was obtained from Vera Gorbunova (University of Rochester, NY). The NHEJ-I vector was linearized with I-SceI and subjected to electrophoresis prior to purification using the Qiagen Gel Extraction Kit (Qiagen).

For BER, 8-oxoguanine (8-oxoG) was incorporated into the transcribed strand of the DNA sequence encoding the mOrange reporter [34]. By-pass of the 8-oxoG during transcription results in insertion of a C or an A. Only incorporation of an A results in transcript that encodes active mOrange reporter. Repair of 8-oxoG produces transcript with a C that produces inactive mOrange, resulting in decreased mOrange expression.

T98G cells were pre-treated with water or 476 μ M Na₂S for 2 h. Cells were removed from the dish and transfected using solution V, program O16 and the AMAXA Nucleofector (LONZA). At least two transfections for each type of vector and treatment were carried out in each experiment, and triplicate experiments were performed. Each transfection

contained 1.2×10^6 cells and 1 μg linear NHEJ-I vector and 300 ng pDS2Rednuc (Clontech) for the NHEJ assay or 100 ng pMAX:mOrange 8oxoG, 1.8 μg carrier DNA and 100 ng pMAXBFP for the BER assay. Following transfection, cells were treated for 2 h with water or 476 μM Na_2S . Flow cytometry was used to determine the GFP and RFP-expressing cells for NHEJ after 24 and 48 h or mOrange and BFP-expressing cells for BER after 17 h.

NHEJ repair efficiency was calculated as $\frac{\text{GFP}}{\text{RFP}} = \frac{\text{number of GFP}^+\text{cells}}{\text{number of RFP}^+\text{cells}}$

BER repair efficiency was calculated as $\frac{\text{mOrange}}{\text{BFP}} = \frac{\text{number of mOrange}^+\text{cells} * \text{MFI}}{\text{number of BFP}^+\text{cells} * \text{MFI}}$

2.14. Statistical analysis

All experiments were repeated three independent times and data are presented as mean \pm standard deviation (SD) unless otherwise indicated. Student's *t*-test was used for comparison between two groups. One way analysis of variance (ANOVA) with Tukey's post-hoc analysis was used for comparison of > 2 groups. All statistical and regression analyses were performed in GraphPad Prism (GraphPad Software Inc.). Regression coefficients were compared using one-way ANOVA. A *p*-value less than 0.05 was considered statistically significant.

3. Results

3.1. Sodium sulfide selectively kills GBM cells

Studies on the role of H_2S in cancer have yielded conflicting results with disparate studies claiming pro-cancer and anti-cancer effects. Published studies indicate that H_2S may be detrimental for GBM. Knockdown of cystathionine beta synthase (CBS), the major H_2S synthesis enzyme in the brain, increases tumor growth in a mouse xenograft model of GBM [19]. To determine whether H_2S is able to kill GBM cells, T98G and U87 cells were treated with Na_2S , a fast-releasing H_2S donor. A dose dependent reduction in colony formation was measured for T98G and U87 cells treated with Na_2S (Fig. 1B). 476 μM Na_2S resulted in approximately 40% cell killing and was the dose chosen for subsequent experiments. Free sulfide levels in cells were elevated after the 4 h 476 μM Na_2S treatment (Fig. 1C) despite the 5–30 min *in vitro* half-life of Na_2S [25]. Since endothelial cells are important players in GBM treatment-associated toxicity [7] and are expected to be exposed to any adjuvant treatment, the cytotoxicity of 476 μM Na_2S was assessed for cerebral microvascular endothelial cells (hCMEC/D3). Interestingly, treatment with 476 μM Na_2S did not decrease hCMEC/D3 survival (Fig. 1D) even though free sulfide levels were elevated in the cells (Fig. 1C).

3.2. Sodium sulfide induces DNA damage in GBM

A limited number of studies have suggested H_2S can act as a genotoxic agent [21,35]. Increased DNA damage can promote cell death and may contribute to Na_2S GBM cell toxicity. To determine if Na_2S is a genotoxic agent in GBM, DNA damage was quantified using γH2AX immuno-staining. While γH2AX foci are generally suggestive of double strand breaks (DSBs), γH2AX can also increase following other forms of DNA damage [36]. Therefore an increase in γH2AX is an indicator of an increase in DNA damage and possibly DSBs. Treatment with 476 μM Na_2S increased the number of γH2AX foci per cell in T98G and U87 cells with no significant effect in hCMEC/D3 (Fig. 2A and B).

Oxidative base lesions are the most prevalent type of DNA damage in cells with 8-oxoguanine (8-oxoG) being the most common [37]. Previous studies suggest H_2S can induce radical-associated DNA

damage in naked nuclei [38]; however, no published study has examined this in cells with functional antioxidant pathways. The FPG-modified alkaline comet assay was used to assess oxidative base damage, specifically 8-oxoG and formamidopyrimidines. Na_2S increased oxidative base damage in T98G and U87 cells, and to a lesser degree in hCMEC/D3 cells (Fig. 3). This assay detects single strand breaks (SSB) and alkali-labile sites when the cells are not treated with FPG. T98G cells also had a significant increase in SSB following treatment with Na_2S (Fig. 3B).

3.3. Sodium sulfide does not inhibit NHEJ or BER repair

An increase in DNA damage can result from either an induction of damage or a decrease in repair. To determine whether Na_2S inhibits DNA repair, we used DNA repair reporter plasmids to assess NHEJ, the major pathway for DSB repair, and 8-oxoguanine glycosylase (OGG1)-mediated BER in T98G cells. For NHEJ, the NHEJ-I vector [33] was linearized with I-SceI, which removes an adenoviral exon that disrupts the GFP coding region. Active GFP is only produced if the I-SceI DSB is repaired in the cells by NHEJ. GFP-expression was measured at 24 and 48 h and no significant difference was found between treated and untreated cells (Fig. 4A).

For BER, 8-oxoguanine (8-oxoG) was incorporated into the transcribed strand of the DNA sequence encoding the mOrange reporter [34]. Only incorporation of an A in the transcript during by-pass of the 8-oxoG produces active mOrange reporter. A decrease in BER prevents removal of 8-oxoG and results in an increase in mOrange expression. Initial experiments examined expression at ~6, 17 and 40 h post-transfection of the T98G cells. The optimal mOrange expression was after 17 h. Triplicate experiments were performed measuring mOrange expression at 17 h post-transfection but no significant difference was found between treated and untreated cells (Fig. 4B).

3.4. Sodium sulfide increases oxidative stress in GBM

Excess ROS can increase oxidative DNA damage. Glutathione is an important cellular antioxidant that maintains redox balance and a lower GSH:GSSG ratio is an indicator of oxidative burden. T98G and U87 cells treated with Na_2S had higher GSSG levels and lower GSH:GSSG ratio compared to untreated cells (Fig. 5A). Strikingly, Na_2S had the reverse effect in hCMEC/D3: an increase in the GSH level was measured in treated cells that resulted in a higher GSH:GSSG ratio. An increase in total ROS in GBM cells was also measured using the redox-sensitive fluorescent probe, CM- H_2DCFDA . This increase was attenuated by treatment with 2.5 μM TEMPOL (Fig. 5B).

3.5. Sodium sulfide has differential effects on mitochondrial function

The mitochondria are a major source of cellular ROS and complex I and III of the electron transport chain (ETC) are implicated in ROS production [39]. Electron leak at these complexes can result in one electron reductions of oxygen into superoxide ($\text{O}_2^{\cdot-}$) and the probability of electron leak increases with decreased mitochondrial respiration [40]. T98G and U87 cells treated with Na_2S had significantly lower basal OCR than untreated cells, while Na_2S increased basal OCR in hCMEC/D3 (Fig. 6A and B). Na_2S had no effect on spare capacity, which is defined as the FCCP OCR minus the basal OCR (Fig. 6C). To determine whether Na_2S impairs complex I or III in Na_2S -treated cells, complex I and III activities were measured in cell lysates from T98G and hCMEC/D3 cells treated with degassed water or Na_2S . Na_2S significantly decreased complex III but not complex I activity in T98G cells and had no effect on these activities in hCMEC/D3 (Fig. 6D and E).




Fig. 1. Sodium sulfide is cytotoxic to GBM but not human cerebral microvascular endothelial cells. Cells were treated with Na₂S for 4 h with media change and replacement at 2 h (A). The dose response of T98G and U87 cells to Na₂S was determined using clonogenic survival. The dashed green line indicates the position of Surviving Fraction = 1 on the graph. Data was analyzed using a one-way ANOVA with Tukey's post-hoc analysis (B). Free sulfide levels were measured after the 4 h treatment with 476 μM Na₂S using HPLC. Data was analyzed using a Student's t-test comparing 0 and 476 μM for each cell line (C). The effect of 476 μM Na₂S on hCMEC/D3 was also determined using clonogenic survival. Data was analyzed using a Student's t-test comparing 0 and 476 μM (D). All data are from 3 independent experiments. Error bars represent SD and * represents P < 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

3.6. Sodium sulfide sensitivity in GBM is dependent on a functional electron transport chain

Thirteen components of the ETC are encoded by mitochondrial DNA (mtDNA) [41]. Rho zero (ρ⁰) cells lack mitochondrial DNA and a functional ETC. Attempts to produce ρ⁰ T98G cells were unsuccessful, but PCR to detect cytochrome b confirmed the ρ⁰ status of the U87 ρ⁰ and LN18 ρ⁰ cells obtained from Dr. Berridge (Fig. 7A). U87 ρ⁰ cells did not form colonies and could not be used for the clonogenic assay. However, in agreement with data from the T98G and U87 cells, LN18

ρ⁺ cells were sensitive to Na₂S and 476 μM Na₂S reduced survival by 30% (Fig. 7B). Na₂S had no significant effect on LN18 ρ⁰ cell survival even at the higher dose of 909 μM Na₂S, which reduced survival of the LN18 ρ⁺ cells by over 40%.

3.7. Sodium sulfide sensitizes GBM to ionizing radiation

Photon and proton ionizing radiation (IR) damages DNA to kill cells. Since Na₂S induces DNA damage in T98G and U87 cells, 476 μM Na₂S was investigated for its efficacy as a radiosensitizer. T98G cells were




Fig. 2. Sodium sulfide induces DNA double-strand break formation in GBM. Representative images of γH2AX foci following treatment with 476 μM Na₂S or degassed water for 4 h are shown (A). The number of foci per cell was quantified with JCount Pro using the same parameters for all cell types and replicates (B). Analysis was performed on 150 cells pooled from 3 independent experiments and error bars represent standard error of the mean (SEM). * represents P < 0.05 using a Student's t-test.






Fig. 3. Sodium sulfide increases oxidative DNA base damage. The alkaline comet assay with FPG treatment was used to detect oxidative base damage following 0 or 476 μM Na_2S treatment for 4 h (A) and the tail moment was measured using OpenComet (B). Analysis was performed on 3 independent experiments with at least 50 cells in each experiment. Error bars represent SD and * represents $P < 0.05$ using a Student's t-test.

irradiated at 0–10 Gy using photons and protons in the presence or absence of Na_2S and the data fitted to a linear quadratic model to calculate the RBE_{10} and DEF_{10} . T98G cells had a proton RBE_{10} of 1.2, which is in close agreement with clinically accepted values [42]. Na_2S had a DEF_{10} of 1.34 for both photons and protons at 10% survival (Fig. 8A and Table 1). Na_2S did not sensitize hCMEC/D3 to photons or protons at a clinically relevant dose of 2 Gy (Fig. 8B). The α or β parameters for the LQ were compared for the IR survival curves with and without Na_2S using one-way ANOVA and the P values for the α (P_α) or β (P_β) parameters were < 0.05 , respectively, for both photons and protons (Table 1).



8-oxoguanine results in functional mOrange that was detected 17 h after transfection via flow cytometry. Data is expressed as $\text{mOrange}^+ \times \text{MFI}$ normalized to $\text{BFP}^+ \times \text{MFI}$ as a transfection control (B). Error bars represent SD. Data was analyzed using a Student's t-test to compare treated and untreated cells at a particular time point.

3.8. DNA damage induction by ionizing radiation and sodium sulfide

To examine how the combination treatment altered the induction of DNA damage, the comet assay was performed and γH2AX foci/cell were measured (Fig. 9). Na_2S tended to increase oxidative base damage following IR as assessed by the comet assay; however, it was not statistically significant (Fig. 9A).

Data from the measurement of γH2AX foci/cell at each time point were compared using a one-way ANOVA. As expected, both photons and protons induced γH2AX foci in T98G cells and levels were elevated after IR at 0 and 2 h compared to 0 Gy ($P < 0.05$ Fig. 9B and C).

Fig. 4. Sodium sulfide does not affect DSB repair and OGG1-directed BER. T98G cells were pretreated with 476 μM Na_2S or degassed water for 2 h, transfected with reporter plasmid, and treated for an additional 2 h. For non-homologous end joining, repaired plasmids encode functional GFP and fluorescent expression was detected 24 and 48 h post-transfection using flow cytometry. Data is expressed as $\text{GFP}^+/\text{RFP}^+$ to normalize for transfection efficiency (A). To assess BER, mOrange plasmid containing an 8-oxoguanine was co-transfected with pMaxBFP into T98G cells. Transcriptional mutagenesis of




Fig. 5. Sodium sulfide increases oxidative stress and ROS formation in GBM. GSH and GSSG levels were measured using HPLC to calculate the GSH:GSSG ratio after 4 h of treatment with 0 or 476 $\mu\text{M Na}_2\text{S}$ (A). ROS was measured using CM-H₂DCFDA. Cells were pretreated with TEMPOL for 1 h and then 476 $\mu\text{M Na}_2\text{S}$ or degassed water was also added to the cells. New media with only 476 $\mu\text{M Na}_2\text{S}$ or degassed water was added to the cells after 2 h. Data are expressed as a fold change relative to respective controls. N = 3 for U87, N = 4 for T98G and hCMEC/D3 cells (B). Error bars represent SD and * represents $P < 0.05$ using a paired Student's t-test.

Treatment with 476 $\mu\text{M Na}_2\text{S}$ further increased γH2AX foci/cell immediately following proton but not photon radiation ($P < 0.05$ Fig. 9B). After 2 h of repair (Fig. 9C), a statistical difference was found between the Na_2S -treated and untreated cells at all IR doses, but by 24 h the only difference was between the Na_2S -treated and untreated cells irradiated with 2 Gy protons. This suggests that less repair occurred of the DNA damage induced by Na_2S and protons compared to protons or photons alone, or Na_2S and photons.

A two-way ANOVA with Tukey's post-hoc test was also used to analyze γH2AX foci/cell data for each treatment group at 0, 2 and 24 h to assess DNA repair over time. Without Na_2S treatment, the γH2AX foci/cell induced by photons were significantly different between all the time points, indicating that repair was occurring between 0-24 h. However, for protons alone there was no significant difference for the number of γH2AX foci/cell between 0 and 2 h, but a significant difference was found for 0 and 24 h, and 2 and 24 h ($P < 0.05$). This

indicates that repair occurred between 2 and 24 h, which is slower than photon damage. Addition of Na_2S to either photons or protons resulted in no significant difference for the number of γH2AX foci/cell between 0 and 2 h, but a significant difference was found for 0 and 24 h, and 2 and 24 h ($P < 0.05$).

In summary for the γH2AX foci/cell, repair was detected for photon-induced damage from 0 to 24 h, and the analyses suggest that the addition of the Na_2S inhibited/slowed repair in the first 2 h. Repair of proton or proton and Na_2S -induced damage occurred at 2-24 h, but at 24 h there was still a higher level of γH2AX foci/cell in Na_2S and proton-treated cells versus proton-treated cells (Fig. 9D). This suggests that repair of the damage induced by the combination treatment was slower and hence this damage may be more difficult to repair. An increase in oxidative base damage and DSBs increases the probability of formation of complex clustered lesions, which can be difficult to repair [43]. It is possible that addition of Na_2S to IR increases the complexity




Fig. 6. Sodium sulfide alters mitochondrial function and inhibits complex III activity. Oxygen consumption rate (OCR) was measured in cells treated with 476 $\mu\text{M Na}_2\text{S}$ or degassed water for 4 h using a Seahorse Bioscience XF24 Extracellular Flux Analyzer (A). Basal respiration is the OCR prior to addition of oligomycin (B). The spare capacity was calculated as the FCCP OCR minus the basal OCR (C). Complex I activity was measured as the rotenone-sensitive oxidation of NADH at 340 nm in cell lysate (D). Complex III activity was measured as the antimycin A-sensitive oxidation of cytochrome c at 550 nm in cell lysate (E). All data are from 3 independent experiments. Error bars represent SD and * represents $P < 0.05$ using a Student's t-test. Refer to the web version for easier identification of cell lines in Figure 6A.




Fig. 7. GBM sensitivity to sodium sulfide is dependent on the electron transport chain. U87 and LN-18 ρ^0 were confirmed by PCR using mitochondria specific cytochrome b primers and β -actin as a control (A). Survival of LN18 ρ^+ and ρ^0 following treatment with Na_2S or degassed water for 4 h was determined using clonogenic assay (B). U87 ρ^0 cells did not form colonies. All data are from 3 independent experiments. Error bars represent SD and * represents $P < 0.05$ using a one-way ANOVA with Tukey's post-hoc analysis.





Fig. 8. Sodium sulfide selectively radiosensitizes GBM to ionizing radiation. T98G cells were treated with 476 μM Na_2S or degassed water for a total of 4 h and irradiated during the 4th hr of Na_2S treatment. Surviving fraction at each radiation dose was normalized to their respective controls to account for Na_2S induced killing (A). Data were curve fit to the linear quadratic (LQ) equation to calculate RBE_{10} and DEF_{10} at 10% surviving fraction (SF_{10}). Protons had an $\text{RBE}_{10} = 1.2$. Photons and protons had a $\text{DEF}_{10} = 1.34$. hCMEC/D3 cells were similarly irradiated using a clinically relevant dose of 2 Gy (B) and data analyzed by two-way ANOVA with Tukey's post-hoc for multiple comparison.




Table 1


| Type of IR | LQ (0 μM Na_2S) | LQ (476 μM Na_2S) | P_α | P_β | SF_{10} (0 μM Na_2S) | SF_{10} (476 μM Na_2S) | DEF_{10} |
|------------|---|---|------------|-----------|---|---|-------------------|
| Photon | $SF = e^{-(0.042D+0.028D^2)}$ $R^2 = 0.9385$ | $SF = e^{-(-0.15D+0.084D^2)}$ $R^2 = 0.9645$ | < 0.05 | < 0.05 | 8.30 Gy | 6.21 Gy | 1.34 |
| Proton | $SF = e^{-(0.13D+0.030D^2)}$ $R^2 = 0.9734$ | $SF = e^{-(-0.11D+0.11D^2)}$ $R^2 = 0.9183$ | < 0.05 | < 0.05 | 6.92 Gy | 5.17 Gy | 1.34 |

LQ is the equation for the surviving fraction obtained by fitting the survival data to the linear quadratic equation.

The α or β parameters for the LQ were compared for the IR survival curves with and without Na_2S using one-way ANOVA to obtain the p values for the α (P_α) or β (P_β) parameters, respectively.

SF_{10} is the IR dose that reduced survival by 90%.

DEF_{10} is the Dose Enhancement Factor at 10% survival and is calculated as follows. $\text{DEF}_{10} = \frac{\text{SF}_{10} \text{ 0 } \mu\text{M } \text{Na}_2\text{S}}{\text{SF}_{10} \text{ 476 } \mu\text{M } \text{Na}_2\text{S}}$



using a one-way ANOVA with Tukey's post-hoc analysis but only differences between 0 and 476 μM Na_2S at each IR dose are indicated for simplicity. See text for explanation of the whole analysis.

of the damage induced.

4. Discussion

H_2S is the third identified endogenous gasotransmitter. It is involved in physiologic processes such as vasodilation, inflammation, and neuromodulation [44–46]. Altered H_2S metabolism has been identified in cancers including colon, breast, and GBM [16]. Since endogenously synthesized H_2S has a tumor suppressing role in GBM and other brain cancers [18,19], the effect of exogenous H_2S on GBM cells was tested. For the first time, the fast-releasing H_2S donor, Na_2S , was shown to selectively kill and radiosensitize GBM cells to IR by a mechanism requiring mitochondria and involving ROS and DNA damage.

In this study, Na_2S exhibited a concentration dependent cytotoxic effect on GBM cells at doses below industry established lethal levels (476 μM Na_2S ; 37 ppm H_2S), but at supraphysiologic levels since free sulfide concentrations vary between 20 nM to several micromolar in tissue [47]. Sulfide can exist as H_2S , HS^- , or S^{2-} in solution. At physiologic conditions (pH 7.4, 37 °C), ~20% of sulfide exists as H_2S and 80% as HS^- with minimal amounts of S^{2-} [48]. Given this, 476 μM Na_2S should increase free bioavailable sulfide levels by approximately 95 μM H_2S and 380 μM HS^- . This dose had no effect on cerebral microvascular cell survival, which is in agreement with published work demonstrating doses up to 1 mM Na_2S are not cytotoxic to human umbilical vein endothelial cells (HUVEC) [49]. Although the effect of Na_2S on neurons or astrocytes was not examined here, others have shown H_2S as an antioxidant in the brain [14,50,51].

In contrast to H_2S role as a cytoprotectant, several studies have shown H_2S to be a genotoxic agent. H_2S increases micronuclei formation in lung fibroblasts [21], generates FPG-sensitive lesions in naked nuclei [38], and increases SSBs in supercoiled plasmid under physiologically relevant conditions by a hydrogen peroxide dependent mechanism [52]. This latter study suggests H_2S can produce ROS by chemical reactions independent of cellular mechanisms. Our work demonstrating the induction of $\gamma\text{H}_2\text{AX}$ foci and oxidative base damage by Na_2S in GBM cells with intact antioxidant protection mechanisms is in line with published work.

An increase in DNA damage can be due to induction of damage or inhibition of repair. H_2S has been shown to alter DNA damage and repair signaling via ATR [53] and can also modulate DNA repair protein activity via post-translational sulfhydration [54,55]. However, we did

Fig. 9. DNA Damage Induction by Ionizing Radiation and Sodium Sulfide.

The synergistic effect of 476 μM Na_2S on IR-induced DNA damage was assessed using the alkaline comet assay with FPG treatment (A) or $\gamma\text{H}_2\text{AX}$ foci/cell (B, C, D). T98G cells were treated with 0 or 476 μM Na_2S for a total of 4 h and irradiated with either 1.9 Gy photon or 2 Gy proton during the 4th hour of Na_2S treatment. The comet assay was performed immediately after this 4 h treatment schedule. Analysis was performed on 3 independent experiments with at least 50 cells in each experiment using a one-way ANOVA with Tukey's post-hoc analysis. Error bars represent SD (A). $\gamma\text{H}_2\text{AX}$ foci was quantified immediately after the 4 h treatment schedule (0 h repair time, B) and at 2 (C) and 24 h (D) repair time to determine DSB repair kinetics. Analysis was performed on 150 cells pooled from 3 independent experiments and error bars represent SEM (B, C, D). For all experiments, * represents $P < 0.05$. Each time point was compared

not observe any differences in NHEJ or OGG1-mediated BER suggesting Na_2S is inducing DNA damage. ROS is implicated in this DNA damage induction in T98G and U87 cells as Na_2S decreased the GSH:GSSG ratio and increased CM- H_2DCFDA fluorescence. Interestingly, Na_2S induced a lower level of DNA damage in hCMEC/D3 cells and did not induce CM- H_2DCFDA detectable ROS. This could be explained by the Na_2S treatment increasing GSH levels in hCMEC/D3 cells, which protects the cells from ROS. Other studies have shown H_2S to be protective against oxidative stress in endothelial cells [15,52]. Because the increased ROS in GBM cells was attenuated by TEMPOL, a superoxide dismutase mimetic, it is possible that Na_2S promotes superoxide production in GBM cells.

Mitochondria are a major source of superoxide and ROS [40]. Superoxide is generated in the mitochondria by electrons that escape the ETC and reduce molecular oxygen. The probability of electron leak increases with electron occupancy time or impaired mitochondrial respiration [39,40]. Conversely, increased mitochondrial respiration may decrease superoxide formation. H_2S is a known modulator of mitochondrial activity. At low concentrations, it donates electrons to the ETC while higher concentrations inhibit complex IV [56]. Therefore, mitochondrial stimulation of basal respiration by Na_2S in hCMEC/D3 may be due to electron donation.

Complex I and III are the main generators of mitochondrial ROS [40], but complex I activity was not altered by Na_2S in GBM cells; only complex III activity was diminished. H_2S has a modest reducing potential with a two-electron redox potential of 0.17 V at pH 7 [57]. Inhibition of complex IV by H_2S involves reduction of ferric (Fe^{3+}) heme a_3 to ferrous (Fe^{2+}) heme a_3 [58]. Interestingly, complex III has a mobile Rieske protein with a unique FeS cluster where one Fe is stabilized by histidines instead of cysteines thus giving it a higher midpoint potential ($E_m = \sim 300$ mV) that is comparable to cytochrome a_3 in complex IV ($E_m = \sim 220$ mV) [59,60]. Complex I also contains Fe-S clusters; however, their negative midpoint potentials make them more resistant to reduction by H_2S [61]. Upon reduction by ubiquinol, the Rieske protein in complex III transiently moves from heme b_L to the “ c_1 -position” to facilitate electron transfer to cytochrome c_1 . Impaired oxidation of the Rieske protein as well as maintenance of the Rieske protein away from heme b_L promotes ROS production in *Rhodobacter capsulatus* [62]. It is possible that H_2S reduces complex III activity in GBM cells since it has critical iron containing subunits with appropriate midpoint potentials. Therefore, ROS generation in GBM cells is likely

due to complex III inhibition. To our knowledge, this is the first report of H₂S-mediated complex III inhibition. Inhibition of complex III by Na₂S could increase production of superoxide that is subsequently reduced to H₂O₂ and hydroxyl radicals that damage DNA and promote GBM cell death. To support this, GBM cells without functional ETC (LN-18 ρ⁰ cells) are protected from Na₂S cytotoxicity.

The contrasting effects of H₂S on ROS production, DNA damage, and cell death in GBM and normal brain endothelial cells highlight fundamental differences between cancer and normal cells. Cancer cells preferentially use aerobic glycolysis over oxidative phosphorylation for ATP production [63]. In the present study, complex I and III activity were lower in hCMEC/D3 compared to T98G cells. While this appears contradictory to OCR results where GBM cells had a lower OCR, this difference may be accounted for by inefficient transport of electrons to complex IV where oxygen is reduced and ETC dysfunction in GBM cells consistent with the Warburg effect. The Warburg effect, confers a competitive growth advantage to cancer cells by not only providing energy but also maintaining redox balance and conserving carbons for anabolic metabolism. Specifically, cancer cells have elevated NADPH from the pentose phosphate pathway. NADPH is a critical cofactor in the reduction of GSSG into GSH and oxidized thioredoxin (TRX) to reduced TRX [64]. In fact, we observed higher GSH levels in GBM cells compared to hCMEC/D3. These antioxidants reduce excess reactive oxygen species (ROS) produced by cancer cells and maintain an intermediate level of ROS that allow for normal proliferative signaling as well as tumorigenesis [65]. ROS-directed therapies selectively disrupt redox homeostasis in cancer cells by pushing already-elevated, tumor promoting oxidative stress to even higher, tumor suppressing levels with minimal effect on normal cells with comparatively lower oxidative burden [66]. H₂S may be acting similarly to selectively promote oxidative stress and cell death in GBM.

Several GBM clinical trials have shown increased survival following dose-escalated radiation therapy; however, increased risk of radiation necrosis makes the survival benefit unclear [3–6]. Radiosensitizers could increase the gap in radiation response between cancer and normal tissue to reduce radiation necrosis. In this study, Na₂S radiosensitized T98G cells (DEF₁₀ = 1.34) to both photons and protons likely by enhancing DSBs and oxidative base damage. A dose enhancing factor of 1.34 could significantly affect tumor treatment. An example of an approved and much used radiosensitizer is cisplatin, which is a chemotherapy used in combination with radiation as the standard of care for the treatment of a number of cancers. Cisplatin has a DEF = 1.14 in breast cancer cells [67] and a DEF = 1.4 in squamous cell carcinoma [68].

IR is a DNA damaging agent capable of generating multiple DNA lesions in close proximity (1–2 helical turns) [69]. These clustered lesions are difficult to repair [70,71] and more prevalent following charged particle radiation such as protons [69]. γH2AX foci formed by protons in conjunction with Na₂S were more persistent than foci formed by radiation alone. There was also a significant increase in γH2AX foci/cell between Na₂S and photon compared to photon alone at the 2 h timepoint. This suggests Na₂S may be increasing DNA lesion complexity. Oxidative lesions can occur near DSBs, increasing lesion complexity, and delaying repair that ultimately promotes cell death. Also, repair of closely opposed oxidative base lesions can form DSBs during BER initiation, which may increase γH2AX foci formation at later timepoints [72,73]. This increase in lesion complexity cannot be detected using NHEJ or BER reporter plasmids which only examine repair of the single lesion present in the plasmid. Finally, Na₂S did not synergize with 2 Gy IR in hCMEC/D3. This could be explained by the finding that Na₂S alone did not induce high levels of DNA damage in these cells. This is a critical consideration in radiation therapy since brain endothelial cells are a key player in white matter necrosis [7].

In summary, we show that Na₂S selectively kills GBM cells in culture by inhibiting mitochondrial function, promoting ROS formation, and radiosensitizing GBM cells to both photon and proton therapy. As a CNS

targeted drug, H₂S has several pharmacologically favorable properties. As a gas, it is freely diffusible across the blood brain barrier. Furthermore, inhalation of H₂S gas immediately prior to radiation could rapidly increase its concentration in the brain and promote its use as a radiosensitizer. There are also other sulfide donors with different kinetics (GYY4137), subcellular targeting (AP39), and release mechanisms (DATS) that may potentiate anti-cancer effects [25]. Ideal anti-cancer compounds should also preferentially kill tumor cells and spare normal cells. While the mechanism behind the differential effect of Na₂S in cancer versus normal cells remains unclear, H₂S may be leveraging a fundamental difference in cancer mitochondria resulting from the Warburg effect to increase ROS beyond tolerable levels. It is important to mention that H₂S may have tumorigenic effects at lower concentrations [16]. While 5 μM and 10 μM of Na₂S had no effect on GBM cell survival, we did not examine the effect of lower concentrations on DNA damage and mitochondrial function and this is a limitation of the present study. Future studies are needed to better understand the divergent effects of H₂S in GBM versus normal tissue as well as determine the optimal donor, concentration, and its efficacy *in vivo*.

Disclosures

MRM reports grants from Ion Beam Applications (IBA), outside the submitted work; LRR receives honorarium and is a general stockholder of IBA.

Acknowledgements

This work was supported by the Carroll Feist Predoctoral Fellowship awarded to AYX, an Institutional Development Award (IDeA) from the National Institutes of General Medical Sciences of the NIH under grant number P20GM121307 (CGK), and National Institute of Health grant number CA092584 (ZDN). The authors would also like to thank Creighton France for performing the PCR confirming the rho status of cells and Sophia Nicolosi for preparation of linear DNA for the NHEJ-I plasmid.

References

- [1] J.P. Thakkar, T.A. Dolecek, C. Horbinski, Q.T. Ostrom, D.D. Lightner, J.S. Barnholtz-Sloan, et al., Epidemiologic and molecular prognostic review of glioblastoma, *Cancer Epidemiol. Biomark. Prev.* 23 (10) (2014) 1985–1996.
- [2] R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, *N. Engl. J. Med.* 352 (10) (2005) 987–996.
- [3] M.M. Fitzek, A.F. Thornton, J.D. Rabinov, M.H. Lev, F.S. Pardo, J.E. Munzenrider, et al., Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial, *J. Neurosurg.* 91 (2) (1999) 251–260.
- [4] T. Iuchi, K. Hatano, T. Kodama, T. Sakaïda, S. Yokoi, K. Kawasaki, et al., Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma, *Int. J. Radiat. Oncol. Biol. Phys.* 88 (4) (2014) 793–800.
- [5] M. Tanaka, Y. Ino, K. Nakagawa, M. Tago, T. Todo, High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison, *Lancet Oncol.* 6 (12) (2005) 953–960.
- [6] M. Mizumoto, T. Yamamoto, E. Ishikawa, M. Matsuda, S. Takano, H. Ishikawa, et al., Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide, *J. Neuro Oncol.* 130 (1) (2016) 165–170.
- [7] I. Yang, M.K. Aghi, New advances that enable identification of glioblastoma recurrence, *Nat. Rev. Clin. Oncol.* 6 (11) (2009) 648–657.
- [8] Y.O. Masashi Mizumoto, Koji Tsuboi, Proton beam therapy for intracranial and skull base tumors, *Transl. Cancer Res.* 2 (2) (2013) 87–96.
- [9] J. Jiang, A. Chan, S. Ali, A. Saha, K.J. Haushalter, W.-L.M.L. Lam, et al., Hydrogen sulfide—mechanisms of toxicity and development of an antidote, *Sci. Rep.* 6 (2016) 20831.
- [10] R. Wang, Two's company, three's a crowd: can H₂S be the third endogenous gaseous transmitter? *FASEB J.* 16 (13) (2002) 1792–1798.
- [11] A.K. Mustafa, M.M. Gadalla, N. Sen, S. Kim, W. Mu, S.K. Gazi, et al., H₂S signals through protein S-sulfhydration, *Sci. Signal.* 2 (96) (2009).
- [12] O. Kabil, R. Banerjee, Enzymology of H₂S biogenesis, decay and signaling, *Antioxidants Redox Signal.* 20 (5) (2014) 770–782.
- [13] Y. Kimura, H. Kimura, Hydrogen sulfide protects neurons from oxidative stress,

- FASEB J. 18 (10) (2004) 1165–1167.
- [14] Y. Kimura, Y.-I. Goto, H. Kimura, Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria, *Antioxidants Redox Signal.* 12 (1) (2010) 1–13.
- [15] N. Tyagi, K.S. Moshal, U. Sen, T.P. Vacek, M. Kumar, W.M. Hughes, et al., H₂S protects against methionine-induced oxidative stress in brain endothelial cells, *Antioxidants Redox Signal.* 11 (1) (2009) 25–33.
- [16] D. Wu, W. Si, M. Wang, S. Lv, A. Ji, Y. Li, Hydrogen sulfide in cancer: friend or foe? *Nitric Oxide* 50 (2015) 38–45.
- [17] C. Szabo, C. Coletta, C. Chao, K. Módis, B. Szczesny, A. Papapetropoulos, et al., Tumor-derived hydrogen sulfide, produced by cystathionine- β -synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer, *Proc. Nat. Acad. Sci. U. S. A.* 110 (30) (2013) 12474–12479.
- [18] H. Jurkowska, T. Uchacz, J. Roberts, M. Wróbel, Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation, *Amino Acids* 41 (1) (2011) 131–139.
- [19] N. Takano, Y. Sarfraz, D.M. Gilkes, P. Chaturvedi, L. Xiang, M. Suematsu, et al., Decreased expression of cystathionine β -synthase promotes glioma tumorigenesis, *Mol. Cancer Res. : MCR* 12 (10) (2014) 1398–1406.
- [20] Z.W. Lee, X.Y. Teo, E.Y. Tay, C.H. Tan, T. Hagen, P.K. Moore, et al., Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance, *Br. J. Pharmacol.* 171 (18) (2014) 4322–4336.
- [21] R. Baskar, L. Li, P.K. Moore, Hydrogen sulfide-induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells, *FASEB J. : Off. Pub. Fed. Am. Soc. Exp. Biol.* 21 (1) (2007) 247–255.
- [22] M.S. Attene-Ramos, G.M. Nava, M.G. Mueller, E.D. Wagner, M.J. Plewa, R.H. Gaskins, DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells, *Environ. Mol. Mutagen.* 51 (4) (2010) 304–314.
- [23] W. Shen, S. Li, S.H. Chung, L. Zhu, J. Stayt, T. Su, et al., Tyrosine phosphorylation of VE-cadherin and claudin-5 is associated with TGF- β 1-induced permeability of centrally derived vascular endothelium, *Eur. J. Cell Biol.* 90 (4) (2011) 323–332.
- [24] M.N. Hughes, M.N. Centelles, K.P. Moore, Making and working with hydrogen sulfide: the chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review, *Free Radical Biol. Med.* 47 (10) (2009) 1346–1353.
- [25] C. Szabo, A. Papapetropoulos, International union of basic and clinical pharmacology. CII: pharmacological modulation of H₂S levels: H₂S donors and H₂S biosynthesis inhibitors, *Pharmacol. Rev.* 69 (4) (2017) 497–564.
- [26] X. Shen, G.K. Kolluru, S. Yuan, C.G. Kevil, Measurement of H₂S in vivo and in vitro by the monobromobimane method, *Methods Enzymol.* 554 (2015) 31–45.
- [27] L. Jakl, P. Lobachevsky, L. Vokálová, M. Durdík, E. Marková, I. Belyaev, Validation of JCountPro software for efficient assessment of ionizing radiation-induced foci in human lymphocytes, *Int. J. Radiat. Biol.* (2016) 1–8.
- [28] J.A. Higgins, M. Zainol, K. Brown, G.D.D. Jones, Anthocyanins as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C, *Mutagenesis* 29 (4) (2014) 227–235.
- [29] B.M. Gyori, G. Venkatachalam, P.S. Thiagarajan, D. Hsu, M.-V. Clement, OpenComet: an automated tool for comet assay image analysis, *Redox Biol.* 2 (2014) 457–465.
- [30] B. Wang, Aw T. Yee, K.Y. Stokes, N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes, *Redox biology* 14 (2018) 218–228.
- [31] K.L. Jackson, W.-L.L. Lin, S. Miriyala, R.D. Dayton, M. Panchatcharam, K.J. McCarthy, et al., p62 pathology model in the rat substantia nigra with filamentous inclusions and progressive neurodegeneration, *PLoS One* 12 (1) (2017).
- [32] M. Spinazzi, A. Casarin, V. Pertegato, L. Salvati, C. Angelini, Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells, *Nat. Protoc.* 7 (6) (2012) 1235–1246.
- [33] A. Seluanov, Z. Mao, V. Gorbunova, Analysis of DNA double-strand break (DSB) repair in mammalian cells, *J. Vis. Exp.* (43) (2010).
- [34] Z.D. Nagel, C.M. Margulies, I.A. Chaim, S.K. McRee, P. Mazzucato, A. Ahmad, et al., Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis, *Proc. Nat. Acad. Sci. U. S. A.* 111 (18) (2014) 32.
- [35] M.S. Attene-Ramos, E.D. Wagner, M.J. Plewa, H.R. Gaskins, Evidence that hydrogen sulfide is a genotoxic agent, *Mol. Cancer Res. : MCR* 4 (1) (2006) 9–14.
- [36] I. Revet, L. Feeney, S. Bruguera, W. Wilson, T.K. Dong, D.H. Oh, et al., Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents, *Proc. Nat. Acad. Sci. U. S. A.* 108 (21) (2011) 8663–8667.
- [37] P. Fortini, B. Pascucci, E. Parlanti, M. D'Errico, V. Simonelli, E. Dogliotti, 8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways, *Mutat. Res.* 531 (1–2) (2003) 127–139.
- [38] M.S. Attene-Ramos, E.D. Wagner, R.H. Gaskins, M.J. Plewa, Hydrogen sulfide induces direct radical-associated DNA damage, *Mol. Cancer Res.* 5 (5) (2007) 455–459.
- [39] J.F. Turrens, Mitochondrial formation of reactive oxygen species, *J. Physiol.* 552 (Pt 2) (2003) 335–344.
- [40] M.P. Murphy, How mitochondria produce reactive oxygen species, *Biochem. J.* 417 (Pt 1) (2009) 1–13.
- [41] D.A. Clayton, Transcription and replication of mitochondrial DNA, *Hum. Reprod.* 15 (Suppl 2) (2000) 11–17.
- [42] H. Paganetti, Significance and implementation of RBE variations in proton beam therapy, *Technol. Canc. Res. Treat.* 2 (5) (2003) 413–426.
- [43] E. Sage, L. Harrison, Clustered DNA lesion repair in eukaryotes: relevance to mutagenesis and cell survival, *Mutat. Res.* 711 (1–2) (2011) 123–133.
- [44] K. Abe, H. Kimura, The possible role of hydrogen sulfide as an endogenous neuromodulator, *J. Neurosci. : Off. J. Soc. Neurosci.* 16 (3) (1996) 1066–1071.
- [45] G. Yang, L. Wu, B. Jiang, W. Yang, J. Qi, K. Cao, et al., H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase, *Science* 322 (5901) (2008) 587–590.
- [46] S. Fiorucci, E. Antonelli, E. Distrutti, G. Rizzo, A. Mencarelli, S. Orlandi, et al., Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs, *Gastroenterology* 129 (4) (2005) 1210–1224.
- [47] H. Kimura, Metabolic turnover of hydrogen sulfide, *Front. Physiol.* 3 (2012) 101.
- [48] G.K. Kolluru, X. Shen, S.C. Bir, C.G. Kevil, Hydrogen sulfide chemical biology: pathophysiological roles and detection, *Nitric Oxide : Biol. Chem.* 35 (2013) 5–20.
- [49] S. Yuan, S. Pardue, X. Shen, J.S. Alexander, A.W. Orr, C.G. Kevil, Hydrogen sulfide metabolism regulates endothelial solute barrier function, *Redox biology* 9 (2016) 157–166.
- [50] Y. Kimura, H. Kimura, Hydrogen sulfide protects neurons from oxidative stress, *FASEB J. : Off. Pub. Fed. Am. Soc. Exp. Biol.* 18 (10) (2004) 1165–1167.
- [51] M. Lu, L.-F. Hu, G. Hu, J.-S. Bian, Hydrogen sulfide protects astrocytes against H₂O₂-induced neural injury via enhancing glutamate uptake, *Free Radic. Biol. Med.* 45 (12) (2008) 1705–1713.
- [52] M. Hoffman, A. Rajapakse, X. Shen, K.S. Gates, Generation of DNA-damaging reactive oxygen species via the autooxidation of hydrogen sulfide under physiologically relevant conditions: chemistry relevant to both the genotoxic and cell signaling properties of H(2)S, *Chem. Res. Toxicol.* 25 (8) (2012) 1609–1615.
- [53] J. Chen, X. Shen, S. Pardue, A.T. Meram, S. Rajendran, G.E. Ghali, et al., The Ataxia telangiectasia-mutated and Rad3-related protein kinase regulates cellular hydrogen sulfide concentrations, *DNA Repair* 73 (2019) 55–63.
- [54] B. Szczesny, M. Marcatti, J.R. Zatarain, N. Druzhyina, J.E. Wiktorowicz, P. Nagy, et al., Inhibition of hydrogen sulfide biosynthesis sensitizes lung adenocarcinoma to chemotherapeutic drugs by inhibiting mitochondrial DNA repair and suppressing cellular bioenergetics, *Sci. Rep.* 6 (1) (2016) 36125.
- [55] K. Zhao, Y. Ju, S. Li, Z. Altaany, R. Wang, G. Yang, S-sulphydration of MEK1 leads to PARP-1 activation and DNA damage repair, *EMBO Rep.* 15 (7) (2014) 792–800.
- [56] C. Szabo, C. Ransy, K. Módis, M. Andriamihaja, B. Murghes, C. Coletta, et al., Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms, *Br. J. Pharmacol.* 171 (8) (2014) 2099–2122.
- [57] O. Kabil, R. Banerjee, Redox biochemistry of hydrogen sulfide, *J. Biol. Chem.* 285 (29) (2010) 21903–21907.
- [58] J.P. Collman, S. Ghosh, A. Dey, R.A. Decréau, Using a functional enzyme model to understand the chemistry behind hydrogen sulfide induced hibernation, *Proc. Nat. Acad. Sci. U. S. A.* 106 (52) (2009) 22090–22095.
- [59] J.M. Shifman, B.R. Gibney, R.E. Sharp, P.L. Dutton, Heme redox potential control in de novo designed four-alpha-helix bundle proteins, *Biochemistry* 39 (48) (2000) 14813–14821.
- [60] D.J. Kolling, J.S. Brunzelle, S. Lhee, A.R. Crofts, S.K. Nair, Atomic resolution structures of rieske iron-sulfur protein: role of hydrogen bonds in tuning the redox potential of iron-sulfur clusters, *Structure* 15 (1) (2007) 29–38.
- [61] E.S. Medvedev, V.A. Couch, A.A. Stuchebrukhov, Determination of the intrinsic redox potentials of FeS centers of respiratory complex I from experimental titration curves, *Biochim. Biophys. Acta* 1797 (9) (2010) 1665–1671.
- [62] M. Sarewicz, A. Borek, E. Cieluch, M. wierzczek, A. Osyczka, Discrimination between two possible reaction sequences that create potential risk of generation of deleterious radicals by cytochrome bc₁: implications for the mechanism of superoxide production, *Biochim. Biophys. Acta Bioenerg.* 1797 (11) (2010) 1820–1827.
- [63] O. Warburg, On the origin of cancer cells, *Science* 123 (3191) (1956) 309–314.
- [64] R.A. Cairns, I.S. Harris, T.W. Mak, Regulation of cancer cell metabolism, *Nat. Rev. Canc.* 11 (2) (2011) 85–95.
- [65] S. Galadari, A. Rahman, S. Pallichankandy, F. Thayyullathil, Reactive oxygen species and cancer paradox: to promote or to suppress? *Free Radical Biol. Med.* 104 (2017) 144–164.
- [66] D. Trachootham, J. Alexandre, P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat. Rev. Drug Discov.* 8 (7) (2009) 579–591.
- [67] L. Cui, S. Her, M. Dunne, G.R. Borst, R. De Souza, R.G. Bristow, et al., Significant radiation enhancement effects by gold nanoparticles in combination with cisplatin in triple negative breast cancer cells and tumor xenografts, *Radiat. Res.* 187 (2) (2017) 147–160.
- [68] A.P. Cotrim, M. Yoshikawa, A.N. Sunshine, C. Zheng, A.L. Sowers, A.D. Thetford, et al., Pharmacological protection from radiation \pm cisplatin-induced oral mucositis, *Int. J. Radiat. Oncol. Biol. Phys.* 83 (4) (2012) 1284–1290.
- [69] D.T. Goodhead, Initial events in the cellular effects of ionizing radiations: clustered damage in DNA, *Int. J. Radiat. Biol.* 65 (1) (1994) 7–17.
- [70] L. Harrison, S. Malyarchuk, Can DNA repair cause enhanced cell killing following treatment with ionizing radiation? *Pathophysiology : Off. J. Int. Soc.* 8 (3) (2002) 149–159.
- [71] S. Malyarchuk, R. Castore, L. Harrison, DNA repair of clustered lesions in mammalian cells: involvement of non-homologous end-joining, *Nucleic Acids Res.* 36 (15) (2008) 4872–4882.
- [72] J.O. Blaisdell, L. Harrison, S.S. Wallace, Base excision repair processing of radiation-induced clustered DNA lesions, *Radiat. Protect. Dosim.* 97 (1) (2001) 25–31.
- [73] S. Malyarchuk, R. Castore, L. Harrison, Apex1 can cleave complex clustered DNA lesions in cells, *DNA Repair* 8 (12) (2009) 1343–1354.